quantitative analysis and diagnostic significance of methylated slc19a3 dna in the plasma of breast and gastric cancer patientsdna甲基化的定量分析和诊断意义slc19a3在乳腺癌和胃癌患者的血浆.pdfVIP

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients 1,2. 1. 1 2,4 2,4 Enders K. O. Ng , Candy P. H. Leung , Vivian Y. Shin , Chris L. P. Wong , Edmond S. K. Ma , Hong 3 1 1,2,4,5 Chuan Jin , Kent-Man Chu , Ava Kwong * 1 Department of Surgery, The University of Hong Kong, Hong Kong, Special Administrative Region, People’s Republic of China, 2 Department of Molecular Pathology and Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong, Special Administrative Region, People’s Republic of China, 3 Biomedical Research Center, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China, 4 Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Special Administrative Region, People’s Republic of China, 5 Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America Abstract Background: Previously, we have examined the methylation status of SLC19A3 (solute carrier family 19, member 3) promoter and found that SLC19A3 was epigenetically down-regulated in gastric cancer. Here, we aim to develop a new biomarker for cancer diagnosis using methylated SLC19A3 DNA in plasma. Methodology/Principal Findings: SLC19A3 gene expression was examined by RT-qPCR. Methylation status of SLC19A3 promoter was evaluated by methylation-specific qPCR. SLC19A3 expression was significantly down-regulated in 80% (12/15) of breast tumors (P,0.005). Breast tumors had significant increase in methylation percentage when compared to adjacent non